J 2018

Treatment of infrapopliteal post-PTA dissection with tack implants: 12-month results from the TOBA-BTK study

BRODMANN, Marianne, Christian WISSGOTT, Andrew HOLDEN, Robert STAFFA, Thomas ZELLER et. al.

Základní údaje

Originální název

Treatment of infrapopliteal post-PTA dissection with tack implants: 12-month results from the TOBA-BTK study

Autoři

BRODMANN, Marianne (40 Rakousko, garant), Christian WISSGOTT (276 Německo), Andrew HOLDEN (554 Nový Zéland), Robert STAFFA (203 Česká republika, domácí), Thomas ZELLER (276 Německo), Thodur VASUDEVAN (554 Nový Zéland) a Peter SCHNEIDER (840 Spojené státy)

Vydání

Catheterization and Cardiovascular Interventions, Hoboken, Wiley-Blackwell, 2018, 1522-1946

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.551

Kód RIV

RIV/00216224:14110/18:00104168

Organizační jednotka

Lékařská fakulta

UT WoS

000440646400023

Klíčová slova anglicky

balloon angioplasty; critical limb ischemia; dissection; infrapopliteal arteries; peripheral artery disease; tibial artery

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 11. 2. 2019 15:42, Soňa Böhmová

Anotace

V originále

Objectives: The Tack implant is designed for focal, minimal metal management of dissections. This study evaluated Tacks for treating postpercutaneous transluminal angioplasty (PTA) dissection in patients with below-the-knee (BTK) arterial occlusive disease. Background: PTA is the most commonly used endovascular treatment for patients with occlusive disease of the BTK vessels. Post-PTA dissection is a significant clinical problem that results in poor outcomes, but currently there are limited treatment options for managing dissections. Methods: This prospective, single-arm study evaluated patients with CLI and BTK lesions; 11.4% were Rutherford category (RC) 4 and 88.6% were RC 5. BTK occlusive disease was treated with standard PTA and post-PTA dissections were treated with Tack placement. The primary safety endpoint was a composite of major adverse limb events (MALE) and perioperative death (POD) at 30 days. Other endpoints included: device success; procedure success (vessel patency in the absence of MALE); freedom from clinically driven target lesion revascularization (CD-TLR); primary patency; and changes in RC. Data through 12 months are presented. Results: Thirty-two of 35 (91.4%) patients had post-PTA dissection and successful deployment of Tacks. Procedural success was achieved in 34/35 (97.1%) patients with no MALEs at 30 days. The 12-month patency rate was 78.4% by vessel, 77.4% by patient, and freedom from CD-TLR was 93.5%. Significant (P < .0001) improvement from baseline was observed in RC (75% of patients improved 4 or 5 steps). Conclusion: Tack implant treatment of post-PTA dissection was safe and effective for treatment of BTK dissections and resulted in reasonable 12-month patency and low rates of CD-TLR.